UPLYFT For Lymphoma Survivors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute
About this trial
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Eligibility criteria
Qualifiers
Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
Age ≥ 18 years
Interval of 3 months to 24 months from completion of first-line treatment
In complete remission after first line of treatment
Disqualifiers
Age < 18 years
Concurrent other malignancy
Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
Age < 18 years
Trial design
Treatments tested in this trial
- Interview with Clinicians
- Field Test of UPLYFT with Lymphoma Survivors
- Pilot of UPLYFT with Lymphoma Survivors
Treatment groups
74 Participants
are divided into 3 treatment groupsLocations
1Dana-Farber Cancer Institute02215, BostonMassachusetts, United States
Sponsors and collaborators
Dana-Farber Cancer Institute
Lead sponsor
American Society of Hematology
Collaborator
Source ClinicalTrials.gov